Covance (CVD) Enters a Biomarker Alliance and Services Agreement with Rules-Based Medicine
More News related to CVD
- Covance To Present At The 20th Annual Global Healthcare Services Conference
- Covance Inc. Invites You to Join the Webcast of Its Fourth Quarter 2009 Financial Results Conference Call
- After-Hours Movers 1/27: NFLX, PFBC, ALGN, SOA, ESIO Higher; QCOM, EGHT, TTEK, LSI, SRDX, VRUS Lower
- Covance (CVD) Misses Q4 EPS by 1c; Guides
- Covance Reports Fourth Quarter Revenue of $485M and EPS of $0.64 Per Share
More News related to Corporate News
- Volt Information Sciences (VOL) Updates on Reporting of Audited Financial Statements
- Clarient (CLRT) Launches Lung Cancer Test Insight Dx Pulmotype
- SkyWest (SKYW) Reports 9.9% Increase in RPMs for January 2010.
- Ceradyne (CRDN) Awarded $342K Phase I Contract
- Athersys (ATHX) Gets New Adult Stem Cell Patent
Covance Inc. (NYSE: CVD) announced that it entered into a biomarker alliance and services agreement with Rules-Based Medicine, Inc. (RBM), a leading provider of multiplexed protein biomarker testing to the pharmaceutical industry.
Subject to the terms of the agreement, Covance will use RBM as its exclusive third-party provider of multiplexed protein biomarker testing services, and RBM will use Covance as its exclusive referral source for laboratory testing services.
[SM]
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
